BioNote, Inc. (KRX:377740)
South Korea · Delayed Price · Currency is KRW 4,720.00
-50.00 (-1.05%)
Last updated: Jun 4, 2026, 11:00 AM KST
BioNote Revenue
BioNote had revenue of 32.57B KRW in the quarter ending March 31, 2026, with 14.49% growth. This brings the company's revenue in the last twelve months to 122.44B, up 15.60% year-over-year. In the year 2025, BioNote had annual revenue of 118.32B with 15.12% growth.
Revenue (ttm)
122.44B
Revenue Growth
+15.60%
P/S Ratio
3.94
Revenue / Employee
410.89M
Employees
298
Market Cap
482.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 118.32B | 15.54B | 15.12% |
| Dec 31, 2024 | 102.78B | 12.70B | 14.10% |
| Dec 31, 2023 | 90.08B | -389.58B | -81.22% |
| Dec 31, 2022 | 479.66B | -142.70B | -22.93% |
| Dec 31, 2021 | 622.36B | -9.15B | -1.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SD Biosensor | 718.78B |
| Value Added Technology | 430.30B |
| CLASSYS | 346.88B |
| Vieworks | 243.11B |
| T&L Co., Ltd. | 157.91B |
| Dongbang Medical | 117.37B |
| Shinhung | 104.15B |
| PCL, Inc. | 4.98B |